Microglia-Targeted Lipid Nanoparticles for Aβ Clearance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies aimed at reducing amyloid beta (Aβ) levels in Alzheimer's disease have failed to improve memory, suggesting a need for new approaches to enhance Aβ clearance, and there is a lack of targeted delivery methods to specific cell types in the brain for therapeutic cargo.

Innovation Solution

Lipid nanoparticles (LNPs) are developed to deliver active agents that inhibit the transcription or translation of the human miR17-92 cluster to microglia, utilizing a microglial targeting agent like a mannose moiety to enhance autophagy activity and improve Aβ clearance.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If therapies are directed at removing aggregated Aβ in AD patients, then Aβ amounts are reduced, but memory improvement does not occur

Engineering Contradiction:

ImproveAβ amountsVSAvoidmemory improvement

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent applies preliminary action by using antagomirs to inhibit miR-17 expression before Aβ aggregation can cause significant damage. By blocking the miR-17 pathway upfront, the therapy prevents the downstream effects that lead to neuronal damage, rather than attempting to reverse damage after Aβ accumulation has already occurred. This is evidenced by the use of antagomirs administered prior to or at early stages of AD pathology to prevent rather than merely treat established disease.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent employs an intermediary approach by introducing antagomirs as a mediator between the miR-17 pathway and Aβ metabolism. The antagomir acts as an intermediary molecule that binds to miR-17, preventing it from interfering with autophagy-related genes. This intermediary intervention restores normal autophagy function, which in turn improves Aβ clearance and reduces neuronal damage without directly targeting Aβ itself.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If new approaches are needed to improve the clearance of Aβ, then a better understanding of the underlying defect in Aβ clearance is necessary, but targeted delivery methods to specific cell types in the brain are drastically needed

Engineering Contradiction:

ImproveAβ clearanceVSAvoidtargeted delivery methods

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent applies local quality by designing antagomirs with specific molecular characteristics that enable them to selectively bind to and be taken up by microglia, the brain's immune cells responsible for Aβ clearance. The antagomirs are engineered with specific sequence complements to miR-17 that are expressed in microglia, ensuring localized action at the precise cell type where Aβ clearance defect occurs. This specificity eliminates the need for complex delivery systems while achieving targeted therapeutic effect.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs self-service by utilizing the natural expression patterns and cellular uptake mechanisms of microglia to deliver the therapeutic agent. The antagomirs are designed to be recognized and internalized by microglia through their own physiological processes, such as endocytosis or receptor-mediated uptake, without requiring external delivery vehicles. The microglia essentially service themselves by taking up the antagomir and using it to correct their own functional defect in Aβ clearance.

Inventive Principle:

Principle #25Self-service

3Reliability

If lipid particles comprise an active agent that inhibits transcription or translation of human miR17-92 cluster, then delivery to microglia is enhanced, but the complexity of the composition increases

Engineering Contradiction:

Improvedelivery to microgliaVSAvoidcomposition complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies composite materials by formulating the antagomir within a lipid particle composition. The lipid particle serves as a composite delivery vehicle that encapsulates the antagomir, protecting it from degradation and facilitating its transport to microglia. The composition combines the therapeutic antagomir with lipid materials that provide stability, targeting capability, and cellular uptake enhancement, creating a composite system that achieves reliable delivery while managing complexity through a well-defined formulation approach.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The in vivo delivery of antagomirs within LNPs reduces miR-17 expression in microglia, enhancing autophagy effectors and improving Aβ clearance, thereby mitigating Alzheimer's disease pathology.

Implementation Method 1

one or more lipids comprising a microglial targeting agent (e.g., one or more lipids comprising a carbohydrate moiety such as a mannose moiety) so as to target delivery of the active agent that inhibits the transcription or translation of a human miR17-92 cluster (e.g., an active agent that inhibits the transcription or translation of human miR-17) to the microglia

Methodology Applied

Scientific EffectTargeted delivery:

Implementation Method 2

lipid particles (e.g., lipid nanoparticles) that comprise a nucleic acid that hybridizes to a Mir17-92 cluster under moderate or high stringent conditions

Methodology Applied

Scientific EffectNucleic acid hybridization: